AOD-9604 in Saint-Faustin — Fat Loss Peptide Research Guide
AOD-9604 research guide for Saint-Faustin. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Saint-Faustin looking to source AOD-9604, the first thing to know is that this compound is distributed via specialist online vendors. What this means for Saint-Faustin researchers is that your location matters far less than your ability to verify analytical documentation — and those verification methods are available to every researcher. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis containing HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. The sections below cover what Saint-Faustin researchers need to know about sourcing, verifying, and handling AOD-9604 for scientific research use.
What Studies Say About AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Saint-Faustin comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade AOD-9604
Evaluating AOD-9604 vendors requires starting from the COA: locate the batch-specific certificate before purchasing, not after. Endotoxin testing in the COA is non-negotiable for any injectable research use — endotoxins from bacterial cell wall components can trigger dangerous inflammatory cascades even at trace quantities. Signs of a credible vendor beyond COA quality: documented vendor history spanning multiple years, knowledgeable support capable of explaining COA data, and temperature-appropriate packaging with desiccant. Store lyophilised AOD-9604 at freezer temperature (−20°C) until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order AOD-9604 — ships to Saint-Faustin
COA-verified · International tracking · Research grade
AOD-9604 is sold for research purposes only and is not approved for human therapeutic use by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Proper handling of AOD-9604 requires sterile reconstitution technique — alcohol-swabbed septum, fresh needles, clean working environment — and temperature control throughout the entire workflow. Bacterial endotoxin contamination is the most serious safety risk unique to this class of compound — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. PubMed and related preprint servers provide the most complete literature coverage for AOD-9604 research; favour indexed journal publications over preprints over case reports or anecdotal evidence.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
